Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for muscle and joint recovery in physiotherapy and sports. The company also sells instrumentation and software for body bioimpedance analysis through agents, distributors, and online sales. Pharmanutra S.p.A. was founded in 2000 and is headquartered in Pisa, Italy.…
Berenberg alza le stime sugli utili e resta positiva su PharmaNutra
PHARMANUTRA S.P.A.: IL CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2026
Pharmanutra (BIT: PHN) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 146 employees.
The shares were at 85.80 EUR on 20 November 2026, up 65.0% over 52 weeks. Its 52-week range is 48.95 EUR to 95.90 EUR: the price is 10.5% below the high and 75.3% above the low.
At a market capitalisation of 820.61M EUR, it trades at 36.1 times trailing earnings and 26.0 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 47% for PHN. It pays a dividend yielding 1.38% (it pays out 50% of its earnings), against a median of 1.95% among the dividend payers in that peer group.
Pharmanutra reports return on equity of 28.0%, an operating margin of 22.0% and revenue up 16.9% year over year.
It holds more cash than debt, a net cash position of 5.10M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 96.00 EUR is 11.9% above the current price.